Rodman & Renshaw downgraded Viracta Therapeutics (VIRX) to Neutral from Buy with a price target of 25c, down from $3.50, after Viracta announced it has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas to maximize its cash runway while the board conducts a review of strategic alternatives.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VIRX:
- Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure
- Viracta Therapeutics announces exploration of strategic alternatives
- Viracta Therapeutics Highlights Strategic Focus and Financials
- Viracta Therapeutics reports Q3 EPS (27c) vs (33c) last year
- Viracta Therapeutics expects cash to fund operations into Q1 of 2025
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
